相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Alain P. Algazi et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Timothy A. Yap et al.
CLINICAL CANCER RESEARCH (2014)
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten et al.
INVESTIGATIONAL NEW DRUGS (2014)
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
Melissa Dumble et al.
PLOS ONE (2014)
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
A portrait of AKT kinases - Human cancer and animal models depict a family with strong individualities
A Bellacosa et al.
CANCER BIOLOGY & THERAPY (2004)
分享论文
